<DOC>
	<DOC>NCT00795899</DOC>
	<brief_summary>The present clinical trial will investigate the safety and efficacy of a sequential preoperative therapy with Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression primary breast cancer.</brief_summary>
	<brief_title>Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1. Primary carcinoma of the breast, confirmed histologically by core biopsy (at least 3 core biopsy samples) 2. Tumor lesion of the breast with a palpable or a imagistic size ≥ 2 cm or inflammatory breast cancer 3. Known HER2 status detected on core biopsy. HER2 over expression is defined as DAKO HercepTest (3+) or DAKO HercepTest (2+) and FISH (+) (fluorescenceinsituhybridisation). 4. No distant metastatic disease, confirmed by chest xray, abdominal sonography and bone scan. 5. Female patients 6. Age ≥ 18 and ≤ 65 years 7. ECOG &lt; 2/WHO 01 8. Laboratory requirements GOT and Bilirubin &lt; 1.5x UNL Leukocytes &gt;= 3 G/l Neutrophile &gt; 1 G/l Thrombocytes &gt; 100 G/l Creatinine (Serum) &lt; 2.0 mg/dl. 9. Normal cardiac function, confirmed by cardiologist 10. No active hepatitis 11. Written informed consent for all study procedures 12. Patients must be available and compliant for treatment and followup 1. Multicentricity in various quadrants (contact the study office) 2. CNSmetastases 3. Secondary malignancy, excluding basalioma of the skin or carcinoma in situ of the cervix that has received curative therapy 4. Patients with relevant hemodynamic cardial diseases 5. Patients with a left ventricular ejection fraction (LVEF) under the normal limit of the institution, confirmed by echocardiography or MUGAScan. 6. Uncontrolled, severe comorbidities 7. Patients with severe respiratory diseases and severe dyspnea and / or which need supportive oxygen 8. Previous antiHER2therapy 9. Patients receiving immunosuppressant therapy 10. Known allergy to medication containing cremophor 11. Hb &lt;10 g/dL, Neutrophile &lt;1.5 x109/L, Thrombocytes &lt;100 x109/L. 12. TotalSerumBilirubin &gt;1.5 x ULN (upper limit of normal) (except in patients with confirmed and documented GilbertLereboulletsyndrome), ALT or AST &gt;2.5 x ULN (&gt;5 x ULN by liver metastases), Alkaline Phosphatase &gt;2.5 x ULN (&gt;4 x ULN by liver or bone metastases), Serumcreatinine &gt; 2 x ULN 13. Pregnancy, nursing (a negative pregnancy test must be documented, and safe anticontraceptive measures during pre and postoperative treatment must be implemented) 14. Lack of signed informed consent after informing the patient 15. Lack of willingness to keep and disclose personal medical data as part of the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Safety and efficacy of experimental treatment</keyword>
</DOC>